دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Table of Contents
doi : 10.1016/S1542-3565(22)01140-5
Volume 21, Issue 2, February 2023, Pages A3-A6
Elsewhere in the AGA Journals
doi : 10.1016/S1542-3565(22)01141-7
Volume 21, Issue 2, February 2023, Pages A12-A13
Colonic Actinomycosis Mimicking Malignant Stenosing Tumors
Casper Steenholdt and John Gade
doi : 10.1016/j.cgh.2022.06.020
Volume 21, Issue 2, February 2023, Pages A17-A18
Submucosal Tumor-Like Lesion in Autoimmune Gastritis: A Rare Case of Fundic Gland Type of Gastric Adenocarcinoma
Taro Iwatsubo, Kazuhiro Ota, and Toshihisa Takeuchi
doi : 10.1016/j.cgh.2022.06.021
Volume 21, Issue 2, February 2023, Page A19
A Double Clip Slip
Rita Slim, 1 Carl Safar, 1 and Michael Osseis
doi : 10.1016/j.cgh.2022.06.027
Volume 21, Issue 2, February 2023, Page A20
Blue Notes
CHARLES J. KAHI, MD, MS,
doi : 10.1016/j.cgh.2022.11.021
Volume 21, Issue 2, February 2023, Pages 243-244
2022 American Gastroenterological Association–Center for Gastrointestinal Innovation and Technology Tech Summit
Eric D. Shah, 1 Amrita Sethi, 2 Adarsh M. Thaker, 3 Allison R. Schulman, 4 Sushovan Guha, 5 Jason Samarasena,6 Simon Mathews, 7 and Srinadh Komanduri
doi : 10.1016/j.cgh.2022.08.045
Volume 21, Issue 2, February 2023, Pages 245-249
Promoting Prognostic Understanding and Health Equity for Patients With Advanced Liver Disease: Using “Best Case/Worst Case�
NNEKA N. UFEREAREEJ EL-JAWAHRICHRISTINE RITCHIEJENNIFER C. LAIMARGARET L. SCHWARZE
doi : 10.1016/j.cgh.2022.11.013
Volume 21, Issue 2, February 2023, Pages 250-255
A Framework for Creating a FOAMed Organization in Gastroenterology: Lessons Learned from the Liver Fellow Network
ELIZABETH S. ABYHERSH SHROFFADAM C. WINTERSALYSON KAPLANPARITA PATELALEXANDER S. VOGELADAM MIKOLAJCZYK
doi : 10.1016/j.cgh.2022.08.014
Volume 21, Issue 2, February 2023, Pages 256-259
The Impact of Cascading Accountability on Specialty Practices: Time for a Nested Solution
Lawrence R. Kosinski 1 and Joel V. Brill
doi : 10.1016/j.cgh.2022.11.001
Volume 21, Issue 2, February 2023, Pages 260-263
Rare, Overlooked, or Underappreciated Causes of Recurrent Abdominal Pain: A Primer for Gastroenterologists
Darren M. Brenner, 1 Lawrence J. Brandt, 2 Marc Fenster, 2 Matthew J. Hamilton, 3 Amrit K. Kamboj, 4 Amy S. Oxentenko, 5 Bruce Wang, 6 and William D. Chey
doi : 10.1016/j.cgh.2022.09.022
Volume 21, Issue 2, February 2023, Pages 264-279
Recurrent abdominal pain is a common reason for repeated visits to outpatient clinics and emergency departments, reflecting a substantial unmet need for timely and accurate diagnosis.
Nonalcoholic Fatty Liver Disease Natural History: Role of Mathematical Modeling
JAGPREET CHHATWAL, PhDELLIOT B. TAPPER, MD
doi : 10.1016/j.cgh.2022.01.041
Volume 21, Issue 2, February 2023, Pages 280-282
Disease Progression Modeling for Economic Evaluation in Nonalcoholic Fatty Liver Disease—A Systematic Review
Lina Gruneau,* Mattias Ekstedt,†Stergios Kechagias,†and Martin Henriksson
doi : 10.1016/j.cgh.2021.10.040
Volume 21, Issue 2, February 2023, Pages 283-298
Use of the Esophageal Sponge in Directing Food Reintroduction in Eosinophilic Esophagitis
Jeffrey A. Alexander, 1 Karthik Ravi, 1 Thomas C. Symrk, 2 Tsung-The Wu, 2 Crystal J. Lavey, 1 Debra Geno, 1 Alyssa J. Johnson, 1 Ryan J. Lennon, 3 Margaret H. Collins, 4 Evan S. Dellon, 5 and David A. Katzka 6
doi : 10.1016/j.cgh.2022.05.029
Volume 21, Issue 2, February 2023, Pages 299-306.e3
Long-term Survival After Endoscopic Resection For Gastric Cancer: Real-world Evidence From a Multicenter Prospective Cohort
Haruhisa Suzuki, 1 Hiroyuki Ono, 2 Toshiaki Hirasawa, 3 Yoji Takeuchi,4 Kenji Ishido, 5 Shu Hoteya, 6 Tomonori Yano, 7 Shinji Tanaka, 8 Yosuke Toya, 9 Masahiro Nakagawa, 10 Takashi Toyonaga, 11 Kenichi Takemura, 12 Kingo Hirasawa, 13 Mitsuru Matsuda, 14 Hironori Yamamoto, 15 Yosuke Tsuji, 16 Satoru Hashimoto, 17 Maeda Yuki, 2 Tsuneo Oyama, 18 Ryuta Takenaka, 19 Yoshinobu Yamamoto, 20 Yuji Naito, 21 Katsumi Yamamoto, 22 Nozomu Kobayashi, 23 Yoshiro Kawahara, 24 Masaaki Hirano, 25 Shigeto Koizumi, 26 Shinichiro Hori, 27 Masahiro Tajika, 28 Takuto Hikichi, 29 Kenshi Yao, 30 Chizu Yokoi, 31 Ken Ohnita, 32 Yasuhiro Hisanaga, 33 Tetsuya Sumiyoshi, 34 Shinji Kitamura, 35 Hisao Tanaka, 36 Ryo Shimoda, 37 Taichi Shimazu, 38 Kohei Takizawa, 2 Satoshi Tanabe, 39 Hitoshi Kondo, 34 Hiroyasu Iishi, 4,40 Motoki Ninomiya, 41 and Ichiro Oda,
doi : 10.1016/j.cgh.2022.07.029
Volume 21, Issue 2, February 2023, Pages 307-318.e2
The Natural History of Asymptomatic Gallstones: A Longitudinal Study and Prediction Model
Gareth Morris-Stiff, 1 Shashank Sarvepalli, 2 Bo Hu, 3 Niyati Gupta, 4 Pooja Lal, 4 Carol A. Burke, 5 Ari Garber, 5 John McMichael, 6 Maged K. Rizk,5 John J. Vargo, 5 Mounir Ibrahim, 7 and Michael B. Rothberg
doi : 10.1016/j.cgh.2022.04.010
Volume 21, Issue 2, February 2023, Pages 319-327.e4
Colorectal Sessile Serrated Lesion Detection Using Linked Color Imaging: A Multicenter, Parallel Randomized Controlled Trial
Jun Li,* ,a Di Zhang,* ,a Yunlei Wei,* ,a Kan Chen,* Ruijin Wu,* Kangsheng Peng,* Xiaojia Hou,* Lei Li,* Chao Huang,* Yuxin Wang,* Linjuan Xun,* Hongwei Xu,‡ Jianhua Wang, § Zhirong Chen,k Ming Shen, ¶ and Feng Liu
doi : 10.1016/j.cgh.2022.03.033
Volume 21, Issue 2, February 2023, Pages 328-336.e2
Artificial Intelligence–Assisted Colonoscopy for Colorectal Cancer Screening: A Multicenter Randomized Controlled Trial
Hong Xu, 1,a,b Raymond S. Y. Tang, 2,3,a,b Thomas Y. T. Lam, 3,4,5,a,b Guijun Zhao, 6 James Y. W. Lau, 3,7 Yunpeng Liu, 8 Qi Wu, 9 Long Rong, 10 Weiran Xu, 1 Xue Li, 6 Sunny H. Wong, 2,3,12 Shuntian Cai, 8 Jing Wang, 9 Guanyi Liu, 10 Tantan Ma,1 Xiong Liang, 6 Joyce W. Y. Mak, 2,3 Hongzhi Xu, 8 Peng Yuan, 9 Tingting Cao, 1 Fudong Li, 1 Zhenshi Ye, 8 Zhang Shutian, 11 and Joseph J. Y. Sung
doi : 10.1016/j.cgh.2022.07.006
Volume 21, Issue 2, February 2023, Pages 337-346.e3
Warfarin Is Associated With Higher Rates of Upper But Not Lower Gastrointestinal Bleeding Compared with Direct Oral Anticoagulants: A Population-Based Propensity-Weighted Cohort Study
Arnar B. Ingason, 1,2 Johann P. Hreinsson, 3 Arnar S. Agustsson, 1,2 Sigrun H. Lund, 4 Edward Rumba, 1,2 Daniel A. Palsson, 1,2 Indridi E. Reynisson, 5 Brynja R. Gudmundsdottir, 6 Pall T. Onundarson, 1,6 and Einar S. Bjornsson
doi : 10.1016/j.cgh.2022.06.033
Volume 21, Issue 2, February 2023, Pages 347-357.e10
Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease
Ho Soo Chun,* ,‡ Minjong Lee,* ,‡,a Hye Ah Lee,§ Seo Yeong Oh,* Hyo Jeong Baek,* Jae Won Moon,* Yeon Jeong Kim,k Jinha Lee,k Hyoeun Kim, ¶ Hwi Young Kim,* ,‡ Kwon Yoo,* ,‡ Tae Hun Kim,*,‡ and Seung Up Kim
doi : 10.1016/j.cgh.2021.12.043
Volume 21, Issue 2, February 2023, Pages 358-369.e12
Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study
Hideki Fujii,*,‡ Michihiro Iwaki,§ Hideki Hayashi,jj Hidenori Toyoda, ¶ Satoshi Oeda, #, ** Hideyuki Hyogo,‡‡ Miwa Kawanaka, §§ Asahiro Morishita,jjjj Kensuke Munekage, ¶¶ Kazuhito Kawata, ## Sakura Yamamura,*** Koji Sawada,‡‡‡,§§§ Tatsuji Maeshiro,jjjjjj Hiroshi Tobita, ¶¶¶ Yuichi Yoshida, ### Masafumi Naito, ### Asuka Araki, ¶¶¶ Shingo Arakaki,jjjjjj Takumi Kawaguchi,*** Hidenao Noritake, ## Masafumi Ono,**** Tsutomu Masaki,jjjj Satoshi Yasuda, ¶ Eiichi Tomita,jj Masato Yoneda, § Norifumi Kawada,‡ Akihiro Tokushige,‡‡‡‡ Yoshihiro Kamada, §§§§ Hirokazu Takahashi, # Shinichiro Ueda,jjjjjjjj Shinichi Aishima, ¶¶¶¶ Yoshio Sumida, #### Atsushi Nakajima, § and Takeshi Okanoue,*****
doi : 10.1016/j.cgh.2022.01.002
Volume 21, Issue 2, February 2023, Pages 370-379
Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD
Nobuharu Tamaki,* ,‡ Kento Imajo, §,k Suzanne R. Sharpton,* Jinho Jung,* Nancy Sutter,* Nobuyoshi Kawamura, §,k Masato Yoneda, § Mark A. Valasek, ¶ Cynthia Behling, # Claude B. Sirlin,** Masayuki Kurosaki,‡ Namiki Izumi,‡ Atsushi Nakajima, § and Rohit Loomba
doi : 10.1016/j.cgh.2022.01.023
Volume 21, Issue 2, February 2023, Pages 380-387.e3
Myosteatosis, but not Sarcopenia, Predisposes NAFLD Subjects to Early Steatohepatitis and Fibrosis Progression
Yun-Cheng Hsieh,* ,‡,a Sae Kyung Joo, §,a Bo Kyung Koo,jj Han-Chieh Lin,* ,‡ Dong Hyeon Lee, § Mee Soo Chang, ¶ Jeong Hwan Park, ¶ Young Ho So, # and Won Kim, § on behalf of the Innovative Target Exploration of NAFLD (ITEN) Consortium
doi : 10.1016/j.cgh.2022.01.020
Volume 21, Issue 2, February 2023, Pages 388-397.e10
Inverse Association Between Serum 25-Hydroxyvitamin D and Nonalcoholic Fatty Liver Disease
Shuai Yuan* and Susanna C. Larsson
doi : 10.1016/j.cgh.2022.01.021
Volume 21, Issue 2, February 2023, Pages 398-405.e4
Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors
Juan Carlos Rodriguez-Duque,* ,‡ José Luis Calleja, § Paula Iruzubieta,* ,‡ Marta Hernández-Conde, § Coral Rivas-Rivas,* ,‡ MarÃa Isabel Vera, § Maria Jose Garcia,* ,‡ Marta Pascual,*,‡ Beatriz Castro,*,‡ AgustÃn GarcÃa-Blanco,‡ Enrique GarcÃa-Nieto,‡ Soraya Curiel-del Olmo,‡ MarÃa Luisa Cagigal,k Lorena Lopez-Montejo,‡ Tatiana Fernández-Lamas,‡ Laura Rasines,‡ José Ignacio Fortea,* ,‡ José Pedro Vaque,‡,¶ Yza Frias, § Montserrat Rivero,* ,‡ MarÃa Teresa Arias-Loste,*,‡,b and Javier Crespo*
doi : 10.1016/j.cgh.2022.01.039
Volume 21, Issue 2, February 2023, Pages 406-414.e7
The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States
Nabihah Tayob,* Fasiha Kanwal,‡,§,jj,¶ Abeer Alsarraj,‡,§,jj,¶ Ruben Hernaez,‡,§,jj,¶ and Hashem B. El-Serag
doi : 10.1016/j.cgh.2022.01.047
Volume 21, Issue 2, February 2023, Pages 415-423.e4
Long-term Evolution of Estimated Glomerular Filtration Rate in Patients With Antiviral Treatment for Hepatitis C Virus Infection
Chen-Hua Liu,* ,‡,§ Jou-Wei Lin, § Chun-Jen Liu,* ,‡,jj Tung-Hung Su,* ,‡ Jo-Hsuan Wu, ¶ Tai-Chung Tseng,* ,‡,# Pei-Jer Chen,* ,‡,jj and Jia-Horng Kao
doi : 10.1016/j.cgh.2022.01.050
Volume 21, Issue 2, February 2023, Pages 424-434.e5
Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease
Biyao Zou,* ,‡ Michelle C. Odden,‡ and Mindie H. Nguyen
doi : 10.1016/j.cgh.2022.01.057
Volume 21, Issue 2, February 2023, Pages 435-444.e6
Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium
Mary E. Rinella,* ,‡,a Sanjaya K. Satapathy, §,a Danielle Brandman,k Coleman Smith, ¶ Sal Elwir, # Jonathan Xia,‡ Meg Gibson,‡ Carlos Figueredo,** Mounika Angirekula,‡‡ Jason M. Vanatta, §§ Raiya Sarwar,kk Yu Jiang, §§ Dyanna Gregory,‡ Tandy Agostini, ¶ JimIn Ko, ¶ Pradeep Podila, ¶¶ Grace Gallo,‡ Kymberly D. Watt,‡‡,b and Mohammad S. Siddiqui ##,
doi : 10.1016/j.cgh.2022.02.028
Volume 21, Issue 2, February 2023, Pages 445-455.e2
Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis
Parambir S. Dulai, 1 Brian G. Feagan, 2 Bruce E. Sands, 3 Jingjing Chen, 4 Karen Lasch, 5 and Richard A. Lirio
doi : 10.1016/j.cgh.2022.07.027
Volume 21, Issue 2, February 2023, Pages 456-466.e7
Appendectomy and Future Risk of Microscopic Colitis: A Population-Based Case-Control Study in Sweden
John Maret-Ouda,1,2 Jennifer C. Ström, 2 Bjorn Roelstraete, 1 Louise Emilsson, 1,3,4,5 Amit D. Joshi, 6,7 Hamed Khalili, 6,7,8 and Jonas F. Ludvigsson
doi : 10.1016/j.cgh.2022.05.037
Volume 21, Issue 2, February 2023, Pages 467-475.e2
Skeletal Muscle–Derived Cell Implantation for the Treatment of Fecal Incontinence: A Randomized, Placebo-Controlled Study
Andrea Frudinger, 1 Annett Gauruder-Burmester,2 Wilhelm Graf, 3 Jan-Peter Lehmann, 4 Ulf Gunnarsson, 5 Minko Mihov, 6 Peter Ihnát, 7 Pavle Kosorok, 8 Julius Orhalmi, 9 Petr Slauf, 10 Anton Emmanuel, 11 Vladislav Hristov, 12 Anna Jungwirthova, 13 Paul-Antoine Lehur, 14 Andreas Müller, 15 Melanie Amort, 16 Rainer Marksteiner, 16 and Marco Thurner
doi : 10.1016/j.cgh.2022.07.039
Volume 21, Issue 2, February 2023, Pages 476-486.e8
Biopsy of Non-tumor Sites After Biopsy of a Colorectal Cancer is not Associated With Metachronous Cancers: AÂ Case-control Study
Angela Y. Lam,1 Jeffrey K. Lee, 1,2 Sophie Merchant, 2 Christopher D. Jensen, 2 Mai Sedki, 2 and Douglas A. Corley
doi : 10.1016/j.cgh.2022.05.006
Volume 21, Issue 2, February 2023, Pages 487-496.e3
Racial and Ethnic Disparities in Early-Onset Colorectal Cancer Survival
Timothy A. Zaki, 1 Peter S. Liang, 2,3 Folasade P. May, 4 and Caitlin C. Murphy 5
doi : 10.1016/j.cgh.2022.05.035
Volume 21, Issue 2, February 2023, Pages 497-506.e3
Cost-Effectiveness of Earlier or More Intensive Colorectal Cancer Screening in Overweight and Obese Patients
Aaron Yeoh, Ajitha Mannalithara, and Uri Ladabaum
doi : 10.1016/j.cgh.2022.07.028
Volume 21, Issue 2, February 2023, Pages 507-519
Patient Preferences for Colorectal Cancer Screening Tests in Light of Lowering the Screening Age to 45 Years
Katherine E. Makaroff, 1,2 Jaspreet Shergill, 3 Marie Lauzon, 4 Carine Khalil, 1 Sangeeta C. Ahluwalia, 5,6 Brennan M. R. Spiegel, 1,2,3,6,7,8,9,10 and Christopher V. Almario
doi : 10.1016/j.cgh.2022.07.012
Volume 21, Issue 2, February 2023, Pages 520-531.e10
Induction Efficacy of Upadacitinib in Therapy-Refractory Crohn’s Disease: A Retrospective Case Series
JAGODA POKRYSZKA, MD SIEGLINDE REINISCH, MD CHRISTIAN PRIMAS, MD GOTTFRIED NOVACEK, MD WALTER REINISCH, MD
doi : 10.1016/j.cgh.2022.01.004
Volume 21, Issue 2, February 2023, Pages 532-534.e3
Spleen Size Does Not Correlate With Histological Stage of Liver Disease in People With Nonalcoholic Fatty Liver Disease
TESSA M. CACCIOTTOLO, MD, PhDANUPA KUMAR, MBBSEDMUND M. GODFREY, MA, FRCRSUSAN E. DAVIES, FRCPathMICHAEL ALLISON, MD, PhD
doi : 10.1016/j.cgh.2022.01.007
Volume 21, Issue 2, February 2023, Pages 535-537.e1
Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients
JOANNE K. LIUPHILIP VUTIEN, MD, MSDANIEL Q. HUANG, MBBSMASATOSHI ISHIGAMI, MD, PhDCHARLES S. LANDIS, MD, PhDMINDIE H. NGUYEN, MD, MAS
doi : 10.1016/j.cgh.2022.01.035
Volume 21, Issue 2, February 2023, Pages 538-540.e4
Early Biologic Initiation After Chronic Pouch Inflammation Diagnosis Does Not Impact Clinical Outcomes
MAIA KAYAL, MD DAVID KOHLER, BA JEAN FREDERIC COLOMBEL, MD MARLA C. DUBINSKY, MD RYAN C. UNGARO, MD
doi : 10.1016/j.cgh.2022.01.033
Volume 21, Issue 2, February 2023, Pages 541-542.e1
Geographic Variation in Colorectal Cancer Incidence Among Asian Americans: A Population-Based Analysis 2006–2016
CRCCHRISTINA P. WANG, MDJENNY J. LIN, MD, MPHSHAILJA C. SHAH, MDMICHELLE KANG KIM, MD, PhD
doi : 10.1016/j.cgh.2022.01.026
Volume 21, Issue 2, February 2023, Pages 543-545.e3
Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study
ANNA S. LOKJUHI MOONKENNETH E. SHERMANMANDANA KHALILIDAWN FISHBEINK. RAJENDER REDDY
doi : 10.1016/j.cgh.2022.01.059
Volume 21, Issue 2, February 2023, Pages 546-548.e4
Effect of Hormonal Replacement Therapy on Gastroesophageal Reflux Disease and its Complications in Postmenopausal Women
SHERIF SALEH, MDSOPHIE TRUJILLO, DOSARA GHONEIM, MDCHARLES THOMAS, BARONNIE FASS, MD
doi : 10.1016/j.cgh.2022.01.058
Volume 21, Issue 2, February 2023, Pages 549-551.e3
Fully Covered Self-expanding Stents are Cost-effective at Remediating Biliary Strictures in Patients With Chronic Pancreatitis
NIKHIL R. THIRUVENGADAMMONICA SAUMOYYECHESKEL SCHNEIDERMICHAEL L. KOCHMAN
doi : 10.1016/j.cgh.2022.02.019
Volume 21, Issue 2, February 2023, Pages 552-554.e4
Exam 1: Rare, Overlooked, or Underappreciated Causes of Recurrent Abdominal Pain: A Primer for Gastroenterologists
doi : 10.1016/j.cgh.2022.11.022
Volume 21, Issue 2, February 2023, Pages e1-e3
Does NAFLD Prevalence Data Expire?
LAURENS A. VAN KLEEF, MD IBRAHIM AYADA, MD ROBERT J. DE KNEGT, MD, PhD
doi : 10.1016/j.cgh.2022.02.049
Volume 21, Issue 2, February 2023, Page 555
Reply
YEE HUI YEO, MD, MScMICHAEL H. LE, MSMINDIE H. NGUYEN, MD, MAS
doi : 10.1016/j.cgh.2022.03.039
Volume 21, Issue 2, February 2023, Page 556
GALAD Score for HCC Screening and Surveillance
ANURAG SACHAN, MDSARASWATI KUSHWAH, MDAJAY DUSEJA, MD, DM
doi : 10.1016/j.cgh.2022.03.028
Volume 21, Issue 2, February 2023, Pages 556-557
Immunomodulator Withdrawal From Anti-TNF Therapy Needs a Careful Patient Selection
SUPRABHAT GIRI, MBBS, MD, DMSUSHRUT INGAWALE, MBBS, MDSUMASWI ANGADI, MBBS, MD, DNB
doi : 10.1016/j.cgh.2022.02.012
Volume 21, Issue 2, February 2023, Pages 557-558
Reply
REMI MAHMOUD JOHANNES P. D. SCHULTHEISS HERMA H. FIDDER BAS OLDENBURG
doi : 10.1016/j.cgh.2022.04.004
Volume 21, Issue 2, February 2023, Pages 558-559
Considerations on Self-Expandable Metallic Stents in Treatment of Malignant Biliary Strictures
GUANJUN ZHANG, MDYAQI ZHAI, MD, PHDMINGYANG LI, MD, PHD
doi : 10.1016/j.cgh.2022.03.026
Volume 21, Issue 2, February 2023, Page 559
Response to: Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications, by Jerome Boursier et al
THIERRY POYNARD, MD, PhD OLIVIER DECKMYN DOMINIQUE VALLA, MD, PhD
doi : 10.1016/j.cgh.2022.03.040
Volume 21, Issue 2, February 2023, Pages 559-560
Reply
MARINE ROUX, PhD JEROME BOURSIER, MD, PhD
doi : 10.1016/j.cgh.2022.05.023
Volume 21, Issue 2, February 2023, Pages 560-561
Daily Step Count as Prognostic Marker in Cirrhosis: So Close yet so Far!
SURENDER SINGH, MD, DMNIKHIL BUSH, MD, DMSUNIL TANEJA, MD, DM
doi : 10.1016/j.cgh.2022.04.005
Volume 21, Issue 2, February 2023, Page 561
Reply
ANDRES DUARTE-ROJO, MD, PhDFEI-PI LIN, MDPAMELA M. BLOOMER, PT, MPT
doi : 10.1016/j.cgh.2022.05.025
Volume 21, Issue 2, February 2023, Pages 561-562
